Orbimed Advisors LLC Has $127.45 Million Position in Alnylam Pharmaceuticals, Inc. (ALNY)

Orbimed Advisors LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 69.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,084,800 shares of the biopharmaceutical company’s stock after buying an additional 445,600 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 1.2% of Orbimed Advisors LLC’s holdings, making the stock its 28th largest holding. Orbimed Advisors LLC owned approximately 1.17% of Alnylam Pharmaceuticals worth $127,453,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. State of Wisconsin Investment Board lifted its position in shares of Alnylam Pharmaceuticals by 0.7% during the second quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the last quarter. Utah Retirement Systems lifted its position in shares of Alnylam Pharmaceuticals by 1.5% during the second quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 200 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 200 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Alnylam Pharmaceuticals by 0.8% during the second quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock worth $3,818,000 after purchasing an additional 398 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 393,212 shares of company stock worth $48,109,436. Insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at $130.89 on Friday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals, Inc. has a 52 week low of $35.98 and a 52 week high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business’s quarterly revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.21) EPS. equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

Several analysts have recently weighed in on ALNY shares. Needham & Company LLC reiterated a “buy” rating and set a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. BMO Capital Markets reiterated an “outperform” rating and set a $99.00 target price (down from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Instinet started coverage on Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $110.00 target price (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Leerink Swann reiterated a “market perform” rating and set a $72.00 target price (down from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $121.85.

COPYRIGHT VIOLATION NOTICE: This report was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/10/orbimed-advisors-llc-has-127-45-million-position-in-alnylam-pharmaceuticals-inc-alny.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply